Breaking News Drops As (AMIX) Enrolls Human Clinical Trial (On Breakout Watch Now)

Time's ticking to get AMIX on radar immediately. Breaking News Drops As (AMIX) Enrolls Human Clinical Trial (On Breakout Watch Now) March 6th Dear Reader, Time's ticking to get AMIX on radar immediately. AMIX could soon become a major breakout target after dropping breaking news today! Take a look at the company's PR: Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Bn-Dollar Pancreatic Cancer Market First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has commenced patient enrollment for its proof-of-concept (PoC) human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain. ... [Read the full article here.]( Remember, this is a [low float idea]( with fewer than 9Mn shares. That means volatility can appear at the drop of a hat (especially after major news like AMIX's today). Get AMIX on your radar before it's too late. ----- Autonomix Medical, Inc. (AMIX) Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. How Autonomix Uses This Science Scientists have long known the nervous system is how the body interprets pain, but until now there’s been no way to navigate it to provide precise treatment. The Autonomix catheter-based technology acts like a precision guided smart bo-mb, allowing doctors to find and destroy the specific target nerves, through ablation or burning, that are misfiring to alleviate pain. About Autonomix's Technology With their catheter-based sensing technology, they're developing the ability to do two things at once: sense neural signals that indicate pain or disease and destroy those nerves at the source. Autonomix believes this is a better alternative to the current approaches commonly used today, where doctors treat suspected areas in an attempt to hit the right nerves. This approach is often inaccurate and can miss the target and even cause collateral damage to surrounding nerves. The Autonomix technology uses their proprietary microchip and unique antenna sensing array to deliver precise treatments through a simple and safe transvascular procedure. How It Works STEP 1 - Proprietary Microchip The Autonomix catheter is equipped with a microchip that converts analog signals from the body to a digital signal that can be sent directly to a computer screen. This means the faint neural signals don’t have to travel through several feet of wires—they’re read right on the spot. STEP 2 - Sensing Antenna Array Their sensing antenna is sensitive enough to detect signals as low as 0.5 microvolts (as opposed to the 10-15 microvolt minimum detectable by current technology). The unique basket design can locate neural signals in a 3D space for the most precise treatment possible. STEP 3 - Simple, Minimally Invasive Procedure Autonomix's technology is designed to do more than just locate neural signals. In the future, with just a single quick procedure, they will be able to locate, ablate and confirm successful ablation of specific nerves. Get The Full Picture Here: [Autonomix's Website.]( ----- And as I mentioned above, AMIX has several potential catalysts to soak in right now. Take a look: #1. With Backing From A Low Float, AMIX Could Become A Volatile Situation (At Any Given Moment). According to the [Yahoo Finance]( website, AMIX has a low float. The website reports this profile to have approximately 8.65Mn shares in its float. Why is that important? It's important on one crucial level. Volatility. Could more positive company news in early 2024 provide a near term spark? #2. Proof-of-Concept In Lead Target Indication Opens Up a >$100Bn Market Opp. Significant Unmet Need Pancreatic cancer-related pain is a daunting issue, primarily due to its location near critical nerves and vessels, leading to severe, resistant pain. Traditional pain treatments, including opioids, frequently prove inadequate, leaving countless patients in desperate need of more effective solutions. Speed to Market Pancreatic cancer and pancreatitis-related pain, though smaller markets, offer distinct development benefits that can accelerate their market entry, especially in terms of clinical trials. Smaller patient population often translates to shorter enrollment times and decreasing trial durations. Achieving “proof-of-concept” in this area opens the door to blockbuster diseases, expanding the horizons for their technology. Cost of Development Developing a treatment for a large blockbuster mark is expensive. By initially targeting pancreatic cancer and pancreatitis-related pain, smaller markets, Autonomix is able to leverage a number of cost-efficient advantages, particularly around clinical trial development. The smaller and shorter clinical trials potentially translate to more efficient resource utilization, minimizing overall development costs. [Read more here.]( #3. New To The Nasdaq, Company Visibility Could Grow Significantly After Recent IPO. Autonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ ... [Read the full article here.]( #4. Moving Towards Human Clinical Trials At Breakneck Speed (Huge February Of Momentous Announcements). Last month, AMIX dropped several press releases to express the momentum they are building towards human clinical trials. Check them out: 2/29/24 - [Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial]( 2/22/24 - [Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study]( 2/16/24 - [Autonomix Begins Human POC Clinical Trial Targeting Multi-Bn-Dollar Pancreatic Cancer Market]( Keep a close eye on AMIX's news feed moving forward as they move towards human clinical trials. ------ AMIX Recap - Multiple Potential Catalysts That Could Provide A Breakout Spark #1. With Backing From A Low Float, AMIX Could Become A Volatile Situation (At Any Given Moment). #2. Proof-of-Concept In Lead Target Indication Opens Up a >$100Bn Market Opp. #3. New To The Nasdaq, Company Visibility Could Grow Significantly After Recent IPO. #4. Moving Towards Human Clinical Trials At Breakneck Speed (Huge February Of Momentous Announcements). ----- Coverage is officially initiated on Autonomix Medical, Inc. (AMIX). Get this Nasdaq profile on your screen before it's too late! I'll be in touch with updates when available. Talk soon. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Ownership of FI has now moved to a single individual. Disclosure: I am not a lic-ensed fina-ncial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Fierce full disclosure is to be read and fully understood before using Fierce's website, or joining Fierce's email or text list. By viewing Fierce's website and/or reading Fierce's email or text newsletter you are agreeing to -> [( An owner of SWN Media LLC owns and operates smallcapfirm . com (“SCF”), owns and operates stockwirenews . com (“SWN”), and owns and operates stockstreetwire . com ("SSW"). From time to time, SWN, SCF, FI, and/or SSW will publicly disseminate information about a company via website, email, SMS and other points of media. Pursuant to an agreement between SWN Media LLC and TD Media LLC, FierceInvestor has been hired for a period beginning on 3/5/24 and ending on 3/6/24 to publicly disseminate information about (AMIX) via Website, Email and SMS. SWN Media LLC was paid twenty thousand USD via bank wire transfer. We own zero shares of (AMIX). A member of SWN Media LLC is also a member of TD Media LLC. Pursuant to an agreement between TD Media LLC and JRZ Capital LLC, TD Media LLC has been hired for a period beginning on 03/5/2024 and ending on 03/6/2024 to publicly disseminate information about (AMIX:US) via digital communications. We have been paid fifty thousand dollars USD. We own zero shares of (AMIX:US). [( Fierce | 4834 NW 2nd Ave, Unit #388, Boca Raton, FL 33431 [Unsubscribe {EMAIL}]( [Update Profile]( | [Constant Contact Data Notice]( Sent by jaks@fierceanalyst.ccsend.com